Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Cell Biol. 2013 Dec;91(6):526-31. doi: 10.1139/bcb-2013-0052. Epub 2013 Sep 13.

Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.

Author information

1
a Laboratory of Medical Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.

Abstract

Resistance to paclitaxel is common for treatment of breast cancer. Programmed cell death 5 (PDCD5) accelerates apoptosis in different cell types in response to various stimuli; moreover PDCD5 has been shown to be down-regulated in many tumors. In this study, protein levels of PDCD5 were found to be up-regulated in paclitaxel-treated MDA-MB-231 breast cancer cells. MTT, CCK-8, and clonogenic assays have shown that recombinant human PDCD5 (rhPDCD5) alone could not produce an obvious growth inhibition. However, upon paclitaxel triggering apoptosis, rhPDCD5 protein potentiated chemotherapeutic drugs-induced growth arrest in MDA-MB-231, SK-BR-3, and ZR-75-1 breast cancer cells. In vivo, we use a human breast cancer xenograft model to study. We found that rhPDCD5 dramatically improves the antitumor effects of paclitaxel treatment by intraperitoneal administration. These data suggest that rhPDCD5 has the potential to use as a therapeutic agent to enhance the paclitaxel sensitivity of breast cancer cells.

PMID:
24219296
DOI:
10.1139/bcb-2013-0052
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center